Rezamand, GholamrezaEstêvão, M. DulceMorvaridzadeh, MojganAkbari, AbolfazlTabaeian, Seidamir PashaPizarro, Ana BeatrizMalekahmadi, MahsaHasani, MotaharehRoffey, Darren M.Mirzaei, AlirezaHeshmati, Javad2022-12-122022-12-122022-02http://hdl.handle.net/10400.1/18620Purpose: There is growing evidence that bone health is decreased in individuals with HIV infection. Vitamin D deficiency is also highly prevalent among HIV-infected patients. The literature was systematically reviewed to determine whether bone health and bone-related parameters may improve with vitamin D supplementation in HIV-infected individuals. Methods: Four databases were systematically searched for randomized clinical trials of vitamin D supplementation in HIV infection, published from January 1990 to September 2021. No language or publication restrictions were applied. Standardized mean differences (SMD) with 95% CIs are reported. A random-effects model was used to perform meta-analysis. Findings: Ten studies met the inclusion criteria (N = 733 participants at study completion). The mean ages of the patients in the included trials ranged from 10 to 49 years. The meta-analysis indicated that with vitamin D supplementation, serum 25-hydroxy vitamin D (25[OH]D) level was significantly increased (SMD, 1.86; 95% CI, 1.02 to 2.70; I-2 = 94.4%), but there were no significant effects on levels of serum 1,25-dihydroxy vitamin D (1,25-[OH](2)D) (SMD, 0.29; 95% CI, -0.07 to 0.64; I-2 = 67.4%), total bone mineral density (SMD, 0.07; 95% CI, -0.23 to 0.37; I-2 = 00.0%), spine bone mineral density (SMD, 0.15; 95% CI, -0.19 to 0.49; I-2 = 17.3%), and parathyroid hormone level (SMD, -0.18; 95% CI, -0.37 to 0.02; I-2 = 1.2%) in HIV-infected patients. (C) 2022 Elsevier Inc.engBone mineral densityHIVParathyroid hormoneVitamin Djournal article10.1016/j.clinthera.2021.12.0121879-114X